Note K - Employment Contract and Deferred Compensation	12 Months Ended
Dec. 31, 2016
Notes to Financial Statements
Employment Contract and Deferred Compensation Disclosure [Text Block]	NOTE K–EMPLOYMENT CONTRACT AND DEFERRED COMPENSATION Employment Contracts As of September 1, 2009, Milestone Scientific entered into a five -year employment agreement with Leonard Osser as its Chief Executive Officer (the "2009 Agreement"). The term of the 2009 Agreement is automatically extended for successive one -year periods unless prior to August 1 of any year, either party notifies the other that he or it chooses not to extend the term. Under the 2009 Agreement, the CEO receives base compensation of $300,000 per year. In addition, the CEO, may earn annual bonuses up to an aggregate of $400,000, payable one half in cash and one half in common stock, contingent upon achieving targets set for each year by the Compensation Committee. In addition, if in any year of the term of the agreement the CEO earns a bonus, he shall also be granted five -year stock options to purchase twice the number of bonus shares earned. Each such option is to be exercisable at a price per share equal to the fair market value of a share on the date of grant (110%) of the fair market value if the CEO is a 10% or greater stockholder on the date of grant). The options shall vest and become exercisable to the extent of one - third of the shares covered at the end of each of the first three years following the date of grant, but shall only be exercisable while the CEO is employed by Milestone Scientific or within 30 days after the termination of his employment. In 2012 the CEO waived the option component of his bonus for that year. In accordance with the 2009 Agreement, 855,810 shares of common stock are to be paid out at the end of the term in settlement of $980,906 of deferred compensation accrued at December 31, 2016 and 735,369 shares of common stock are to be paid out at the end of the contract in settlement of $730,985 of deferred compensation accrued at December 31, 2015 and, accordingly, such shares have been classified in stockholders' equity with the common stock classified as to be issued. On December 1, 2016, Wand Dental and Gian Domenico Trombetta (“Trombetta”) entered into an Amended and Restated Employment Agreement (the “Agreement”), pursuant to which Trombetta receives base compensation of $280,000 per year and is eligible to receive annual bonuses in the sole discretion of the Compensation Committee. Pursuant to the Agreement, Trombetta will continue to serve as the Chief Executive Officer of Wand Dental for a period of one -year beginning on September 1, 2016 through August 31, 2017 (the “Employment Term”). The Employment Term automatically renews for a one -year period, from September 1 st through August 31 st of each successive year (each a “Renewal Term”), unless prior to June 1st of the Employment Term or any Renewal Term, as applicable, either party notifies the other that he or it chooses not to extend the term of employment in accordance with the terms of the Agreement.

NOTE

K–EMPLOYMENT CONTRACT AND DEFERRED COMPENSATION

Employment Contracts

As of

September

2009,

Milestone Scientific entered into a

five

-year employment agreement with Leonard Osser as its Chief Executive

Officer (the

"2009

Agreement"). The term of the

2009

Agreement is automatically extended for successive

one

-year periods unless prior to

August

of any year, either party notifies the other that he or it chooses not to extend the term. Under the

2009

Agreement, the CEO receives base compensation of

$300,000

per year. In addition, the CEO,

may

earn annual bonuses up to an aggregate of

$400,000,

payable

one

half in cash and

one

half in common stock, contingent upon achieving targets set for each year by the Compensation Committee. In addition, if in any year of the term of the agreement the CEO earns a bonus, he shall also be granted

five

-year stock options to purchase twice the number of bonus shares earned. Each such option is to be exercisable at a price per share equal to the fair market value of a share on the date of grant

(110%)

of the fair market value if the CEO is a

10%

or greater stockholder on the date of grant). The options shall vest and become exercisable to the extent of

one

third

of the shares covered at the end of each of the

first

three

years following the date of grant, but shall only be exercisable while the CEO is employed by Milestone Scientific or within

days after the termination of his employment. In

2012

the CEO waived the option component of his bonus for that year.

In accordance with the

2009

Agreement,

855,810

shares of common stock are to be paid out at the end of the term in settlement of

$980,906

of deferred compensation accrued at

December

31,

2016

and

735,369

shares of

common stock are to be paid out at the end of the contract in settlement of

$730,985

of deferred compensation accrued at

December

31,

2015

and, accordingly, such shares have been classified in stockholders' equity with the common stock classified as to be issued.

December

2016,

Wand Dental and Gian Domenico Trombetta (“Trombetta”) entered into an Amended and Restated Employment Agreement (the “Agreement”), pursuant to which Trombetta receives base compensation of

$280,000

per year and is eligible to receive annual bonuses in the sole discretion of the Compensation Committee. Pursuant to the Agreement, Trombetta will continue to serve as the Chief Executive Officer of Wand Dental for a period of

one

-year beginning on

September

2016

through

August

31,

2017

(the “Employment Term”). The Employment Term automatically renews for a

one

-year period, from

September

through

August

of each successive year (each a “Renewal Term”), unless prior to

June

1st

of the Employment Term or any Renewal Term, as applicable, either party notifies the other that he or it chooses not to extend the term of employment in accordance with the terms of the Agreement.